Conclusions
treatment-resistant
PRIMARY ALDOSTERONISM, UNCONTROLLED HYPERTENSION
Oral administration of baxdrostat was safe and well tolerated in all subjects and resulted in dose-proportional increases in plasma baxdrostat with a half-life that supports once-daily dosing. The dose-dependent decrease in plasma aldosterone at doses ≥1.5 mg and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of baxdrostat for treatment-resistant or uncontrolled hypertension and primary aldosteronism.